Mark Neumann is EVP, Chief Commercial Officer of Intra-Cellular Therapies, Inc.. Currently has a direct ownership of 29,700 shares of ITCI, which is worth approximately $2.56 Million. The most recent transaction as insider was on Apr 08, 2022, when has been sold 86,348 shares (Common Stock) at a price of $12.73 per share, resulting in proceeds of $1,099,210. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 29.7K
0% 3M change
34.49% 12M change
Total Value Held $2.56 Million

Mark Neumann Transaction History

Date Transaction Value Shares Traded Shares Held Form
Apr 08 2022
BUY
Exercise of conversion of derivative security
$1,099,210 $12.73 p/Share
86,348 Added 39.6%
131,687 Common Stock
Feb 24 2022
SELL
Open market or private sale
$411,903 $52.1 p/Share
7,906 Reduced 14.85%
45,339 Common Stock
Feb 23 2022
BUY
Exercise of conversion of derivative security
-
7,906 Added 12.93%
53,245 Common Stock
Feb 22 2022
SELL
Open market or private sale
$615,096 $55.22 p/Share
11,139 Reduced 19.72%
45,339 Common Stock
Feb 18 2022
BUY
Exercise of conversion of derivative security
-
11,139 Added 16.47%
56,478 Common Stock
Jan 10 2022
SELL
Open market or private sale
$856,354 $40.88 p/Share
20,948 Reduced 31.6%
45,339 Common Stock
Jan 08 2022
BUY
Exercise of conversion of derivative security
-
20,948 Added 24.01%
66,287 Common Stock
Oct 18 2021
SELL
Open market or private sale
$539,937 $40.15 p/Share
13,448 Reduced 22.88%
45,339 Common Stock
Oct 15 2021
BUY
Exercise of conversion of derivative security
-
13,448 Added 18.62%
58,787 Common Stock
Feb 19 2021
SELL
Open market or private sale
$202,591 $39.08 p/Share
5,184 Reduced 10.26%
45,339 Common Stock
Feb 18 2021
BUY
Exercise of conversion of derivative security
-
11,139 Added 18.06%
50,523 Common Stock
Jan 11 2021
SELL
Open market or private sale
$310,082 $32.02 p/Share
9,684 Reduced 19.74%
39,384 Common Stock
Jan 08 2021
BUY
Exercise of conversion of derivative security
-
20,948 Added 29.92%
49,068 Common Stock
Oct 16 2020
SELL
Open market or private sale
$182,026 $26.8 p/Share
6,792 Reduced 19.45%
28,120 Common Stock
Oct 15 2020
BUY
Exercise of conversion of derivative security
-
13,448 Added 27.81%
34,912 Common Stock
MN

Mark Neumann

EVP, Chief Commercial Officer
New York, NY

Track Institutional and Insider Activities on ITCI

Follow Intra-Cellular Therapies, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ITCI shares.

Notify only if

Insider Trading

Get notified when an Intra Cellular Therapies, Inc. insider buys or sells ITCI shares.

Notify only if

News

Receive news related to Intra-Cellular Therapies, Inc.

Track Activities on ITCI